Reuters logo
BRIEF-Esperion initiates of phase 2 triplet oral therapy study
March 7, 2017 / 2:07 PM / 9 months ago

BRIEF-Esperion initiates of phase 2 triplet oral therapy study

March 7 (Reuters) - Esperion Therapeutics Inc:

* Esperion announces initiation of phase 2 triplet oral therapy study of bempedoic acid/ezetimibe/atorvastatin

* Esperion Therapeutics Inc - top-line results are expected by Q4 of 2017 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below